GERN
Geron Corporation
There isn't enough reported data to score GERN yet.
GERN Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
GERN's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
GERN PE Valuation
GERN has no meaningful PE right now: it lost money over the past year. If it returns to profit as analysts expect, today's price would be 19x next year's earnings.
GERN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Returning to profit | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect GERN to return to profit, with revenue growing.
GERN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.05 | — |
| Q3 2026 | -$0.08 | +$0.04 |
| Q2 2026 | -$0.11 | +$0.02 |
| Q1 2026 | -$0.11 | +$0.10 |
| Q4 2025 | -$0.13 | +$0.14 |
| Q3 2025 | -$0.12 | +$0.19 |
| Q2 2025 | -$0.13 | +$0.22 |
| Q1 2025 | -$0.21 | +$0.13 |
| Q4 2024 | -$0.27 | +$0.05 |
GERN is still losing money, but far less than before: $0.08 per share over the past year, against $0.39 at its worst in early 2020.
GERN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $60.2M | +27% |
| Q2 2026 | $57.5M | +17% |
| Q1 2026 | $51.8M | +31% |
| Q3 2025 | $47.2M | +67% |
| Q2 2025 | $49M | +5460% |
| Q1 2025 | $39.6M | +12927% |
| Q3 2024 | $28.3M | +17138% |
| Q2 2024 | $882K | +2941% |
GERN's revenue has grown year over year for nine quarters in a row: $60M last quarter, up 23% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 9.6% | +39 points |
| Q2 2026 | -22% | +3.7 points |
| Q1 2026 | 0.3% | +43 points |
| Q3 2025 | -29% | +70 points |
| Q2 2025 | -25% | +7836 points |
| Q1 2025 | -42% | +18423 points |
| Q3 2024 | -100% | +28932 points |
| Q2 2024 | -7861% | +171281 points |
GERN's operating margin was 9.6% last quarter, up 35 points from the same quarter a year ago, near the top of its range since 2019.
GERN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $10.3M | +$23.8M |
| Q2 2026 | -$15.8M | +$11.6M |
| Q1 2026 | -$62.9M | -$14.9M |
| Q4 2025 | -$22.1M | +$21.7M |
| Q3 2025 | -$13.6M | +$45.4M |
| Q2 2025 | -$27.4M | +$26.3M |
| Q1 2025 | -$48M | +$14.9M |
| Q4 2024 | -$43.8M | -$2.8M |
GERN has burned cash in almost every quarter: −$91M over the past year, against −$133M the year before.
GERN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.1% | +7.4M shares |
| 1 year | +1.2% | +8.1M shares |
| 3 years | +24% | +130M shares |
| 5 years | +148% | +403M shares |
| Available history | +254% | +484M shares |
GERN has 674M diluted shares, up 1.2% from a year ago.
GERN Net Leverage
GERN's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
GERN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.4 | Neutral |
| Stochastic | 14.7 | Oversold |
GERN's weekly RSI is 36 (neutral) and its Stochastic is 15 (oversold).
GERN PE vs Healthcare Sector
GERN has no meaningful PE right now: it lost money over the past year.
GERN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.11 | 11% below |
| 20 week MA | $1.30 | 24% below |
| 50 week MA | $1.38 | 28% below |
| 100 week MA | $1.55 | 36% below |
| 200 week MA | $2.35 | 58% below |
GERN is in a downtrend: it's below all five of its weekly moving averages, and 58% below its 200-week average.
GERN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $1.38 | $1.62 | +17% |
| 2021 | $1.62 | $1.37 | -15% |
| 2022 | $1.37 | $2.09 | +53% |
| 2023 | $2.09 | $2.11 | +1% |
| 2024 | $2.11 | $3.35 | +59% |
| 2025 | $3.35 | $1.37 | -59% |
| 2026 YTD | $1.37 | $0.99 | -28% |
GERN has finished higher in four of the last six years, two of them by more than 50%. It's down 28% so far in 2026.